Urolithiasis and sleeve gastrectomy: a prospective assessment of urinary biochemical variables

Urolitíase e gastrectomia vertical: uma avaliação prospectiva das variáveis bioquímicas urinárias

INTRODUCTION

The association between obesity and the risk of urinary lithiasis has been extensively reported. The mechanisms underlying this relation are multifactorial1,2. Studies on the urinary biochemistry of patients with obesity have shown alterations that predispose to the formation of urinary stones, including hypercalciuria, hypocitraturia, hyperoxaluria, hyperuricosuria, and acid pH3.

Ironically, patients who undergo surgical treatment for obesity, specifically using procedures with a malabsorptive component, have also an increased risk of urinary lithiasis4. This situation occurs mainly due to hyperoxaluria, hypocitraturia, and reduction of urine volume, which leads to an increase in calcium oxalate super saturation (CaOx SS), facilitating the precipitation process4-6.

Most published articles on the relation between bariatric surgery and urinary lithiasis analyzed patients who underwent Roux-en-Y gastric bypass (RYGB), a procedure with a malabsorptive component responsible for all of the abovementioned urinary biochemical alterations, which increases the risk of urinary stones after surgery4,7. However, there is a lack of data in the literature regarding urinary lithiasis in patients undergoing non-malabsorptive procedures, especially sleeve gastrectomy (SG). Only a few prospective studies have been published and the results are sometimes conflicting5,7.

Therefore, this study aims to prospectively evaluate urinary biochemical alterations related to urolithogenesis processes after SG and determine whether this procedure increases or not the risk of formation of urinary stones.
METHODS

Study design

We recruited patients who underwent laparoscopic SG in our Institution between July 2018 and December 2019. We included patients from both sexes, aged between 18 and 65, with formal indication for bariatric surgery (BMI between 30 and 34.9 kg/m² associated with a severe comorbidity, or BMI between 35 and 40 kg/m² associated with any comorbidity, or BMI > 40 kg/m² regardless of comorbidities). Patients with previous diagnosis of urinary lithiasis (regardless of treatment), preoperative glomerular filtration rate < 60 mL/min/1.73 m² (calculated using the MDRD equation)\(^8\), and use of medications that interfered with the urinary metabolism (diuretics, probenecid, angiotensin-converting-enzyme inhibitors, and angiotensin II receptor blockers) were excluded from the study. Patients with inadequate urine collection were also excluded (see “Technical procedures” below).

Technical procedures

All included patients underwent an abdominal ultrasonography as a screening method for the diagnosis of urinary lithiasis. Those patients who did not present urolithiasis in the ultrasound were evaluated through a 24-h urine collection test at two different moments: seven days prior to surgery and at the 6-month postoperative follow-up. To collect the 24-h urine for testing, patients were instructed to discard the first sample in the morning and collect all subsequent samples, including the first sample in the following morning. Urine samples were stored in a refrigerator (2-8°C) before sending them to the laboratory for analysis. This occurred, in all cases, right after the collection of the last sample.

To estimate the reliability of the collected samples, 24-h urinary creatinine was measured. The normal 24-h urinary creatinine excretion is 955-2,936 mg (or 13-29 mg/kg) for men and 601-1,689 mg (or 9-26 mg/kg) for women\(^9\). Levels of urinary creatinine in a 24-h sample below these normal ranges mean inadequate urine collection, and thus, the sample was excluded from the analysis.

The same laboratory analyzed all samples. The quantitative variables were 24-h urine volume, 24-h urine volume adjusted to body weight, urine pH, 24-h levels of urinary oxalate, calcium, citrate, magnesium, uric acid, and calcium oxalate SS, calculated by the Tiselius index\(^10\).

Statistical analysis

As part of data analysis, a database was created using Microsoft Excel. It was then exported to SPSS 13.0, in which the analysis was performed. The Kolmogorov-Smirnov test was applied to assess the normality of quantitative variables. To analyze paired samples, the Student T-test was used in situations that had a normal distribution. When the hypothesis of normality of distribution was refuted, the Wilcoxon test was applied. All conclusions considered a significance level of 95%.

RESULTS

From 51 candidates for SG during the study period, only 41 fulfilled the study criteria. Among these 41 patients, we excluded seven patients from the analysis due to absence of follow-up and two due to severe postoperative complications (gastropleural fistula), which needed further interventions. Therefore, only 32 patients completed the pre- and postoperative evaluations with 24-h urine collection tests. We included them in the final analysis. The sample comprised 26 (81.2%) women and six (18.8%) men, with a mean age of 40.6 ± 9.8 years. The participants’ self-declared skin color was predominantly white (75%), followed by brown (22%) and black (3%). The mean preoperative BMI was 47.1 ± 8.3 kg/m² and the mean postoperative BMI was 35.5 ± 6.1 kg/m² (p<0.001). Approximately 21.8% of the sample presented Type 2 Diabetes Mellitus in the preoperative period and 46.8% presented hypertension.

Table 1 has the values of urinary biochemical variables at pre- and postoperative periods of SG. Urinary creatinine levels certified the reliability of the studied samples. Although some presented a tendency of variation, there was no statistically significant alteration in the values of urinary pH, oxalate, calcium, citrate, and magnesium. Urine volume was significantly lower at the
postoperative evaluation in absolute values (2,242.50 ± 798.26 mL x 1,240.94 ± 352.39 mL, p<0.001) and adjusted to body weight (18.58 ± 6.92 mL/kg x 13.92 ± 4.65 mL/kg, p<0.001). CaOx SS increased significantly after SG (0.11 ± 0.10 x 0.24 ± 0.18, p<0.001). Moreover, uric acid levels were significantly lower at the postoperative evaluation (482.34 ± 195.80 mg x 434.75 ± 158.38 mg, p=0.027).

Table 1. Biochemical variables of the 24-h urine collection test.

| Variable                  | Pre Mean ± SD | Post Mean ± SD | p-value |
|---------------------------|---------------|----------------|---------|
| Creatinine (mg)           | 1,302.61 ± 498.37 | 1,299.53 ± 320.91 | 0.953*  |
| pH                        | 5.86 ± 0.60   | 6.02 ± 0.52     | 0.229** |
| Volume (mL)               | 2,242.50 ± 798.26 | 1,240.94 ± 352.39 | < 0.001* |
| Volume/body weight (mL/kg)| 18.58 ± 6.92  | 13.92 ± 4.65     | < 0.001* |
| CaOx SS#                  | 0.11 ± 0.10   | 0.24 ± 0.18      | < 0.001* |
| Oxalate (mg)              | 7.23 ± 4.00   | 8.32 ± 2.94      | 0.140*  |
| Calcium (mg)              | 84.53 ± 62.69 | 82.03 ± 49.57    | 0.505*  |
| Citrate (mg)              | 366.59 ± 282.74 | 368.66 ± 253.97 | 0.849*  |
| Magnesium (mg)            | 51.25 ± 26.35 | 52.34 ± 20.68    | 0.708*  |
| Uric acid (mg)            | 482.34 ± 195.80 | 434.75 ± 158.38  | 0.027*  |

Pre - preoperative evaluation; Post - postoperative evaluation; CaOx SS - calcium oxalate super saturation; (*) Student t test; (**) Wilcoxon test; (#) Tiselius index - AP(CaOx) = 1.9 x Calcium0.84 x Oxalate x Citrate-0.22 x Magnesium0.12 x Volume-1.03.

**DISCUSSION**

The onset of urolithiasis in patients undergoing bariatric surgery generally occurs one to two years after the procedure. The mean interval is 1.5-3.6 years between surgery and diagnosis11-14. Nevertheless, urinary metabolic alterations can be identified earlier, precisely between the 2nd and 6th postoperative months, as Agrawall et al. reported4. In our study, 24-h urine samples were collected, and we analyzed them six months after SG. We observed some characteristics that may contribute to the formation of urinary stones, such as an important reduction in urine volume (both absolute values and adjusted to body weight) and an increase in CaOx SS.

Studies analyzing patients undergoing malabsorptive procedures established a correlation between these procedures and, reported the occurrence of lithogenic urinary metabolic alterations15,16. Espino-Grosso and Canales showed, in a recent review, that patients who undergo RYGB generally present higher levels of urinary oxalate, increased CaOx SS, lower urine volume, and hypocitraturia. These factors cause an increased risk of urolithiasis7. Moreover, the authors observed that, apparently, purely restrictive bariatric surgeries do not increase the risk of formation of urinary stones, despite leading to a reduction in 24-h urine volume, which is a potential risk factor for this condition.

Regarding non-malabsorptive bariatric procedures, the literature reports scarce and conflicting results. Some authors have raised the hypothesis that these procedures could also increase the risk of urolithiasis due to the reduction in urine volume17. Others have pointed to another direction by suggesting that these procedures would not increase the risk of formation of stones because they do not lead to hyperoxaluria, which is a consequence of malabsorptive operations18. Chen et al. found, in a retrospective study with 85 patients followed for 26.8 months after SG, that the incidence of urolithiasis in these patients was very low: only 5.25 per 1,000 person-year19. The authors, however, did not study the urinary biochemical profile of their samples.

In the present study, we observed a significant reduction in total urine volume after SG (2,242.5mL/24-h x 1,240.94mL/24-h, p<0.001). Because the considerable postoperative weight loss, this could have been responsible for these reductions in urine volume, we also analyzed this variable by adjusting it to body weight. We also found a significant decrease after surgery (18.58mL/
Kg/24h x 13.92 mL/Kg/24h, p<0.001). These findings are in accordance with previous reports. They can be justified by reduction of water intake, early satiety, and faster gastric emptying, observed after operations with a restrictive component\textsuperscript{5,7,11,18}.

CaOx SS is one of the most important variables to assess the risk of CaOx precipitation in urine\textsuperscript{20}. The increase in CaOx SS has been largely reported after malabsorptive procedures. It is secondary to increased levels of oxalate and decreased levels of citrate in the urine after the operation\textsuperscript{21}. Similarly, in our sample, we observed a significant increase in CaOx SS values (0.11 x 0.24, p < 0.005), however this happened with SG, a non-malabsorptive procedure. Despite this increase, CaOx SS values of all included patients remained below the precipitation threshold (<2) at both pre- and postoperative evaluations. Due to the non-malabsorptive nature of SG, we hypothesized that this increase in CaOx SS may be secondary only to decreased urine volume, which we observed.

Moreover, we found a slight increase in oxalate levels after SG. However, there was no statistical significance (7.23 x 8.32mg/24-h). This was already expected, since hyperoxaluria is a common feature of patients undergoing malabsorptive bariatric surgery\textsuperscript{6,7,22}. The mechanism related to a malabsorptive surgery leading to hyperoxaluria is that the unabsorbed fatty acids bind calcium in the intestines, preventing the formation of gut calcium oxalate, which facilitates the absorption of the unbound oxalate\textsuperscript{23,24}.

Furthermore, obesity is associated with hypercalciuria. The urinary levels of calcium generally decrease after malabsorptive procedures due to a decreased intestinal absorption of this ion\textsuperscript{11}. Durant et al. studied the effects of bariatric surgery on the calcium and thyroid metabolism and found a slight increase in urinary excretion of calcium in RYGB and SG groups, with no statistical significance between them\textsuperscript{25}. In addition, there have been no reports of alterations in calcinuria following SG\textsuperscript{22}. Our results reinforce this result since there was no statistically significant difference between calcium levels at the pre- and postoperative periods of SG.

We also analyzed the levels of citrate and magnesium in urine, since both are important uro lithogenesis inhibitors acting especially against the formation of calcium crystals\textsuperscript{26,27}. Despite presenting slightly higher levels at the postoperative period (no statistical significance), both citrate (366.59mg/24-h) and magnesium (51.25mg/24-h) were below ideal levels (640mg/24-h and 70-120mg/24-h, respectively) before and after SG. This could potentially favor the process of formation of stones because there was no reduction in calcium levels in our sample. Our findings are similar as those of Semins et al., who studied a small group of patients undergoing restrictive procedures (gastric banding or SG, and the authors did not find significant alterations in neither citrate nor magnesium in the postoperative period\textsuperscript{22}. Conversely, RYGB and other malabsorptive procedures contribute to a significant reduction in citraturia and magnesuria, though presenting decreased levels of calcium in urine, which may balance the processes of inhibition versus formation of crystals\textsuperscript{6,7,11}.

Low urinary pH is a common feature in patients with obesity. Generally, it is attributed to insulin resistance\textsuperscript{28}. An acidic urine leads to high concentrations of insoluble uric acid and, consequently, formation of stones\textsuperscript{29,30}. Moreover, studies reported that patients who underwent bariatric surgery, specifically RYGB, could present a persistent low urinary pH\textsuperscript{31,32}. On the other hand, our results show that there were no significant alterations in urinary pH after SG, and that its levels remained within the normal range (5.5 - 6.5) during the whole study period.

Finally, we observed that in both pre- and postoperative periods, urinary uric acid levels remained within the normal range (250-750mg/24-h). However, there was a statistically significant decrease in its levels (482.34 x 434.75mg, p=0.027) in the postoperative period. These findings differ from those of Valezi et al., who observed hyperuricosuria and decreased urinary pH in patients who underwent RYGB\textsuperscript{31}. Our results could be explained by significant weight loss alone. However, the real impacts of bariatric surgery are still not completely elucidated, either of RYGB or SG, on uric acid metabolism\textsuperscript{32}.

The main limitations of the present study are sample size and the relatively short follow-up period. On one hand, a longer follow-up could provide clinical
data regarding the development or not of kidney stones after SG. On the other hand, extending the study period could lead to loss of follow-up, a common problem in prospective studies, which could further reduce our sample. Nevertheless, there are some strengths that deserve attention, especially the well-designed patient selection, excluding individuals who already presented signs of urolithiasis at the preoperative period. The risk of selection bias is thus low.

CONCLUSIONS

Our results show a significant increase in CaOx SS, despite within the normal range, and an important reduction in urine volume. Yet, the urinary levels of uric acid significantly decreased after SG, which could be a protective factor against formation of uric acid stones in these patients. There are no clear variations in urinary pH, oxalate, calcium, citrate, or magnesium, which can vary following malabsorptive procedures. Therefore, the authors conclude that SG may lead to important alterations in the urinary profile. However, this would occur in a milder way than in RYGB. Randomized controlled trials with longer follow-up periods are further needed to determine the real impacts of SG on formation processes of kidney stones.
design, methods, and results from the feasibility study. Am J Kidney Dis. 1992;20(1):18-33
9. Leslie S, Sajjad H, Bashir K. 24-Hour Urine Testing for Nephrolithiasis Interpretation. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Oct 7.
10. Tiselius HG, Sandvall K. How are urine composition and stone disease affected by therapeutic measures at an outpatient stone clinic? Eur Urol. 1990;17(3):206-12.
11. Bhatti UH, Duffy AJ, Roberts KE, Shariff AH. Nephrolithiasis after bariatric surgery: A review of pathophysiologic mechanisms and procedural risk. Int J Surg. 2016;36(Pt D):618-23.
12. Durrani O, Morrisroe S, Jackman S, Averch T. Analysis of stone disease in morbidly obese patients undergoing gastric bypass surgery. J Endourol. 2006;20(10):749-52.
13. Sinha MK, Collazo-Clavell ML, Rule A, Milliner DS, Nelson W, Sarr MG, et al. Hyperoxaluric nephrolithiasis is a complication of Roux-en-Y gastric bypass surgery. Kidney Int. 2007;72(1):100-7.
14. Asplin JR, Coe FL. Hyperoxaluria in Kidney Stone Formers Treated With Modern Bariatric Surgery. J Urol. 2007;177(2):565-9.
15. Lieske JC, Mehta RA, Milliner DS, Rule AD, Bergstrahl EJ, Sarr MG. Kidney stones are common after bariatric surgery. Kidney Int 2015;87(4):839-45.
16. Wu JN, Craig J, Chamie K, Asplin J, Ali MR, Low RK. Urolithiasis risk factors in the bariatric population undergoing gastric bypass surgery. Surg Obes Relat Dis. 2013;9(1):83-7.
17. Cartledge J, Biyani CS, Gkentzis A, Kimuli M, Traxter O. Urolithiasis in inflammatory bowel disease and bariatric surgery. World J Nephrol. 2016;5(6):538.
18. Vijayvargiya P, Anthanont P, Erickson SB, Thongprayoon C, Cheungpasitporn W. The risk of kidney stones following bariatric surgery: a systematic review and meta-analysis. Ren Fail. 2016;38(3):424-30.
19. Chen T, Godebu E, Horgan S, Mirheydar HS, Sur RL. The effect of restrictive bariatric surgery on urolithiasis. J Endourol. 2013;27(2):242-4.
20. Robertson WG. Do “inhibitors of crystallisation” play any role in the prevention of kidney stones? A critique. Urolithiasis. 2017;45(1):43-56.
21. Upala S, Jaruvongvanich V, Sanguankoeo A. Risk of nephrolithiasis, hyperoxaluria, and calcium oxalate supersaturation increased after Roux-en-Y gastric bypass surgery: a systematic review and meta-analysis. Surg Obes Relat Dis. 2016;12(8):1513-21.
22. Semins MJ, Asplin JR, Steele K, Assimos DG, Lingeman JE, Donahue S, et al. The effect of restrictive bariatric surgery on urinary stone risk factors. Urolology. 2010;76(4):826-9.
23. Kwenda EP, Rabley AK, Canales BK. Lessons from rodent gastric bypass model of enteric hyperoxaluria. Curr Opin Nephrol Hypertens. 2020;29(4):400-6.
24. Kumar R, Lieske JC, Collazo-Clavell ML, Sarr MG, Olson ER, Vrtiska TJ, et al. Fat malabsorption and increased intestinal oxalate absorption are common after Roux- en-Y gastric bypass surgery. Surgery. 2011;149(5):654-61.
25. Duran İD, Gülçelik NE, Bulut B, Balci Z, Berker D, Güler S. Differences in Calcium Metabolism and Thyroid Physiology After Sleeve Gastrectomy and Roux-En-Y Gastric Bypass. Obes Surg. 2019;29(2):705-12.
26. Nicar MJ, Hill K, Pak CYC. Inhibition by citrate of spontaneous precipitation of calcium oxalate in vitro. J Bone Miner Res. 1987;2(3):215-20.
27. Vormann J. Magnesium and Kidney Health – More on the “Forgotten Electrolyte.” Am J Nephrol. 2016;44(5):379-80.
28. Maalouf NM, Cameron MA, Moe OW, Adams-Huet B, Sakhaee K. Low urine pH: a novel feature of the metabolic syndrome. Clin J Am Soc Nephrol. 2007;2(5):379-80.
29. Abate N, Chandalia M, Cabo-Chan AV Jr, Moe OW, Sakhaee K. The metabolic syndrome and uric acid nephrolithiasis: novel features of renal manifestation of insulin resistance. Kidney Int. 2004;65(2):386-92.
30. Sohguna A, Bigoniya P. A Review on Epidemiology and Etiology of Renal Stone. Am J Drug Discov Dev. 2017;7(2):54-62.
31. Valezi AC, Fuganti PE, Junior JM, Delfino VD. Urinary evaluation after RYGBP: a lithogenic profile with early postoperative increase in the incidence
of urolithiasis. Obes Surg. 2013;23(10):1575-80.
32. Tarplin S, Ganesan V, Monga M. Stone formation and management after bariatric surgery. Nat Rev Urol. 2015;12(5):263-70.

Received in: 24/08/2020
Accepted for publication: 28/10/2020
Conflict of interest: no.
Funding source: none.

Mailing address:
Fernando Santa-Cruz
E-mail: f.santacruzoliveira@gmail.com